Recruiting OBSERVATIONAL NCT06512259

AlloMend Acellular Dermal Matrix Allograft in Pre-Pectoral Breast Reconstruction

A Retrospective Study To Evaluate The Safety And Effectiveness Of AlloMend® Acellular Dermal Matrix Used In Post Mastectomy Pre-Pectoral Breast Reconstruction And Followed For Up To 6-Months Post-Operatively.

Sponsor: AlloSource

Conditions Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy

Interventions AlloMend® Acellular Dermal Matrix allograft

Updated 4 times since 2024 Last updated: Nov 20, 2025 Started: Oct 19, 2023 Primary completion: Jun 30, 2026 Completion: Dec 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Pre-Pectoral Breast Reconstruction Following Single or Double Mastectomy and is currently actively recruiting participants. AlloSource leads this study, which shows 4 recorded versions since 2023 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

4 versions recorded

Dec 2025 — Present [monthly]

Recruiting
Feb 2025 — Dec 2025 [monthly]

Recruiting
Sep 2024 — Feb 2025 [monthly]

Recruiting
Aug 2024 — Sep 2024 [monthly]

Recruiting

First recorded

Oct 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AlloSource

Data source: AlloSource

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Joliet, United States